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Autoantibodies against the extracellular domain of
bullous pemphigoid antigen 2 (BPAG2) are thought to
play a key role in the pathogenesis of bullous pemphigoid
and their detection may thus be of diagnostic and prog-
nostic value. The aim of this study was to develop a
standardized enzyme-linked immunosorbent assay utiliz-
ing the baculovirus-derived protein BV13 (extracellular
domain of BPAG2 devoid of 68 amino acids at the C
terminus linked to glutathione-S-transferase and 6x His
tag) to detect BPAG2-specific autoantibodies. For the
enzyme-linked immunosorbent assay, nickel agarose
affinity-purified BV13 protein was incubated with sera
from patients with bullous pemphigoid (n J 39), gesta-
tional pemphigoid (n J 10), and pemphigus vulgaris/
pemphigus foliaceus (PV/PF; n J 15), or normal human
sera (NHS; n J 18). Nickel affinity-purified proteins
from wild-type baculovirus-infected insect cells served
Bullous pemphigoid (BP) is an autoimmune blisteringdisorder characterized by subepidermal bullae and circu-lating autoantibodies directed against the basement mem-brane zone of stratified squamous epithelia (Beutneret al, 1968; Stanley et al, 1981). Previous studies have
demonstrated that these autoantibodies react predominantly with two
components of hemidesmosomes, bullous pemphigoid antigen 1
(BPAG1, also termed BP230) and bullous pemphigoid antigen 2
(BPAG2, also BP180 or type XVII collagen) (Stanley et al, 1981; Labib
et al, 1986; Morrison et al, 1988). Hemidesmosomes are multiprotein
complexes that mediate adhesion of epithelial cells to the underlying
basement membrane and connect elements of the cytoskeleton to the
extracellular matrix in skin and other stratified epithelia (Yancey, 1995;
Borradori and Sonnenberg, 1996; Green and Jones, 1996). BPAG1, a
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as a control. A positive enzyme-linked immunosorbent
assay value was defined as reactivity (ODBV13 – ODWT) >
mean reactivity F 1 SD of the negative control sera (PV/
PF; NHS). Thirty-five of 39 bullous pemphigoid sera and
10 of 10 gestational pemphigoid sera were reactive to
BPAG2 compared with none of 15 PV/PF sera and one
of 18 NHS (sensitivity, 91.8%; specificity, 97%). Of 16
BPAG2-reactive sera in the enzyme-linked immunosorb-
ent assay, only six were BPAG2-reactive in the western
blot, whereas 14 sera immunoprecipitated BPAG2 from
extracts of epidermal keratinocytes. The enzyme-linked
immunosorbent assay utilizing an eukaryotic BPAG2
protein thus seems to be highly sensitive and specific in
the detection of BPAG2-specific antibodies and, hence,
may be useful in the diagnosis of bullous autoimmune
diseases, such as bullous pemphigoid and gestational
pemphigoid. Key words: autoimmunity/B lymphocytes/hemi-
desmosome. J Invest Dermatol 110:282–286, 1998
cytoplasmatic plaque constituent of these complexes, belongs to a
family of intermediate filament binding proteins and has been shown
to associate with intermediate filaments in vitro (Green et al, 1992;
Yang et al, 1996). In contrast, BPAG2 is a type II transmembrane
protein that may serve as a cell matrix receptor for a yet unrecognized
ligand within the extracellular matrix (Giudice et al, 1992, 1993, 1994;
Hopkinson et al, 1992; Masunaga et al, 1997). The extracellular
COOH-terminal half contains 15 interrupted collagenous domains that
may form collagen-like triple helices (Giudice et al, 1992; Hirako et al,
1996). Support for the idea that BPAG2 plays an important role in
promoting cell adhesion and the assembly of hemidesmosomes derives
from transfection studies (Hopkinson et al, 1995; Borradori et al,
1996) and from studies of patients with generalized atrophic benign
epidermolysis bullosa, an inherited skin blistering disorder characterized
by defective dermo–epidermal adhesion and the formation of rudiment-
ary hemidesmosomes (McGrath et al, 1995; Jonkman et al, 1995;
Darling et al, 1997). Although almost all autoantibodies from BP sera
target BPAG1, and BPAG2 in approximately half of the cases, their
importance in the pathogenesis of the disease has remained unclear.
Recent studies have shown that rabbit antibodies raised against a major
immunodominant site of the extracellular domain (ECD) of BPAG2
adjacent to the membrane spanning region, are able to induce subepider-
mal blisters, via complement activation, when injected into neonatal
mice (Liu et al, 1993, 1995). These observations strongly suggest that
autoantibodies against BPAG2 are pathogenic and are responsible for
dermo–epidermal separation in BP.
The purpose of this study was to develop an enzyme-linked
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immunosorbent assay (ELISA) for the detection of BPAG2-specific
autoantibodies in patients with BP, utilizing an eukaryotic recombinant
protein consisting of the ECD of BPAG2 produced in a baculovirus
expression system. This eukaryotic expression system generates recom-
binant proteins with post-translational modifications that are frequently
identical to those of the authentic protein (Kidd and Emery, 1993).
To evaluate the sensitivity and specificity of the ELISA using this
recombinant eukaryotic BPAG2 protein, the reactivity of a panel of
sera from patients with BP was compared with those of sera from
patients with gestational pemphigoid (PG), a disease closely related to
BP (Morrison et al, 1988; Jenkins et al, 1995), sera from patients with
pemphigus vulgaris (PV) and pemphigus foliaceus (PF), two bullous
autoimmune skin diseases not related to BP (Amagai et al, 1994), and
sera from healthy donors.
MATERIALS AND METHODS
Patients and controls Serum samples were obtained from adult patients
with generalized BP (n 5 39), PG (n 5 10), PV/PF (n 5 15), and healthy
volunteers (n 5 18). The clinical diagnosis of BP and PG was confirmed by
histopathology (subepidermal blisters) and direct immunofluorescence micro-
scopy (IgG deposits at the dermal–epidermal junction of involved skin). In
addition, these sera contained circulating anti-basement membrane zone IgG
upon analysis in one of the following in vitro tests: (i) indirect immunofluores-
cence microscopy (IgG binding to the epidermal site of 1 M NaCl separated
normal human skin) (BP, n 5 17; PG, n 5 4), (ii) western blots with extracts
from epidermal keratinocytes (BP, n 5 6), or (iii) immunoprecipitation with
biosynthetically radiolabeled extracts from epidermal keratinocytes (BP, n 5
16; PG, n 5 6). All of the 15 PV and PF patients with typical histopathology
and positive direct immunofluorescence of involved skin had circulating
autoantibodies reacting with the surface of epithelial cells of monkey esophagus.
Generation of recombinant BV13 (baculoprotein containing the ECD
of BPAG2 devoid of 68 amino acids at the carboxyl terminus linked to
glutathione-S-transferase and 6x His tag) baculovirus and expression
and purification of recombinant human BPAG2 protein cDNA clones
corresponding to the ECD of BPAG2 were generated by reverse transcriptase-
polymerase chain reaction using total RNA from cultured human keratinocytes
(Masunaga et al, 1997) with primers based on the published sequence of human
BPAG2 (Giudice et al, 1992). A cDNA fragment corresponding to BPAG2
nucleotides 1561–2562 and another to nucleotides 2518–4630 were digested
with Cla1, subcloned into pBluescript II SK1 (Stratagene, La Jolla, CA) via a
three way ligation and sequenced by the dideoxynucleotide method of Sanger
to ensure that the BPAG2 cDNA did not contain any errors. The BPAG2
insert (nucleotides 1561–4630) was subcloned into the baculovirus transfer
vector pAcGHLT-A (Pharmingen, San Diego, CA). This vector expresses the
glutathione S-transferase (GST) affinity tag and the 6x His tag. Due to a single
base substitution (C→T) at nucleotide 4396 resulting at a stop codon at this
site near the 39 end of this cDNA, the baculovirus-encoded recombinant of
the BPAG2 ectodomain used in these ELISA studies, called BV13, lacked 68
amino acids at its carboxyl terminus. Infectious virus was made using the
BaculoGold expression system (Pharmingen). Recombinant BV13 baculovirus
was amplified in spodoptera frugiperda insect cells using a previously described
protocol (Amagai et al, 1994). For the production of BV13 protein, 30 3 106
spodoptera frugiperda insect cells were inoculated in 175 cm2 culture flasks
(Falcon, Oxnard, CA) with culture supernatants containing recombinant baculo-
virus at a multiplicity of infection greater than 10. Baculovirus-infected insect
cells were harvested after 3 d and were lysed for the isolation of intracellular
BV13 protein. In brief, 10 3 106 insect cells were suspended in 1 ml of ice-
cold lysis buffer (Pharmingen) supplemented with 6 M urea for 1 h. After
centrifugation of the lyzed insect cells (2000 3 g, 10 min), supernatants with
solubilized BV13 protein were removed from the pellets. The lysis buffer was
then exchanged with binding buffer of a Nickel-NTA agarose column (Quiagen,
Hilden, Germany) by centrifugation in centriprep-30 vials (Amicon, Beverly,
MA). BV13 protein was purified over nickel-NTA agarose following the
manufacturer’s instructions and was finally gradually dialyzed against phosphate-
buffered saline (PBS) at 4°C for 48 h. The amount of BV13 protein was
analyzed by a commercial kit (Bio-Rad, Munich, Germany). The molecular
weight and immunoreactivity of BV13 was determined by western blot with a
recently described polyclonal rabbit anti-human BPAG2 antibody (Masunaga
et al, 1997) and sera from representative patients with BP, and normal rabbit
and human sera served as negative controls.
Western blot of recombinant BPAG2 protein Purified boiled BV13
protein was run on a 10% tris-glycine gel (Bio-Rad) by sodium dodecyl sulfate
polyacrylamide gel electrophoresis and was then blotted onto nitrocellulose
(Bio-Rad). The nitrocellulose membrane was incubated with BP sera diluted
at 1:20–1:50 in PBS with 5% fat-free milk powder (MP) and 0.05% Tween 20
(all from Bio-Rad) overnight at room temperature. After three washes with
PBS/0.05% Tween, the blotted BV13 protein was incubated with a second,
alkaline phophatase-labeled goat anti-human IgG (H 1 L) antibody (Zymed,
San Francisco, CA) at 1:1000 in PBS/5% MP/0.05% Tween for 2 h at room
temperature. Binding of the second antibody was visualized by incubation of
the nitrocellulose membrane with 5-bromo-4-chloro-3-indolyl-phosphate and
nitroblue tetrazolium as a substrate (Kirkegaard and Perry, Gaithersburg, MD)
for 20 min.
ELISA with recombinant BPAG2 protein Nickel agarose-purified BV13
and wild-type (WT) baculoproteins (2 µg per well) were immobilized on 96
well polystyrene plates (Poly Sorb, Nunc Intermed, Wiesbaden, Germany) by
overnight incubation at 4°C. Wells were blocked with PBS/10% MP/0.05%
Tween for 2 h at 37°C and were then washed three times with PBS/0.05%
Tween. Sera from BP patients and controls (uniformly diluted at 1:20 in PBS/
10% MP) were added in triplicate and were incubated overnight at 4°C. After
three washes with PBS/0.05% Tween, a polyclonal alkaline phosphatase-labeled
goat anti-human IgG (H 1 L) antibody (Zymed) diluted in PBS/5% MP at
1:5000 was added to each well for 2 h at 37°C. After washing again as above,
each well received 100 µl of a substrate solution (p-nitrophenylphosphate;
Kirkegaard and Perry). The optical density (OD) was determined at 405 nm
after 15 min using a Spectramax 250 microplate reader (Molecular Device,
Sunnydale, CA). All extinction data were standardized based on the negative
internal standards, which were set to zero OD units. In preliminary experiments,
several BP sera (n 5 10) were also incubated with immobilized GST protein
as a control to BV13 leading only to minimal binding to GST protein (ODGST
, 0.1). To exclude the possibility that the serum reactivity to BV13 protein in
the ELISA was influenced by reactivity to proteins other than the GST-tagged
BV13 protein expressed by baculovirus-infected insect cells, specific reactivity
to BPAG2 was defined as reactivity to BV13 (ODBV13) minus reactivity to
nickel affinity-purified proteins from insect cells infected with WT baculovirus
(ODWT). The background reactivity of sera with WT protein in the ELISA
(ODWT) ranged from 0.1 to 0.35. Twenty-three of 39 sera from patients with
BP and ten of 15 sera from normal volunteers were analyzed and scored against
known controls in a completely blinded manner to assess the specificity of
the ELISA.
Immunoprecipitation (IP) with biosynthetically radiolabeled protein
extracts from epidermal keratinocytes Subconfluent monolayers of normal
human keratinocytes were biosynthetically radiolabeled for 2 h with [35S]-
methionine (59 µCi per ml; specific activity approximately 1100 Ci per mmol,
New England Nuclear, Boston, MA) in methionine-free media. Radiolabeled
human keratinocyte extracts were processed as described previously and studied
by immunoprecipitation using sera from patients and normal controls as described
previously (Stanley et al, 1981; Basset-Seguin et al, 1990). Immunoprecipitation
samples were studied by polyacrylamide gel electrophoresis and fluorography.
Statistical analysis The plate-to-plate variability of the assay and the day-
to-day variability of the assay fell into a range of less than 10% (data not shown).
The ELISA results obtained from the two negative control groups of sera
[PV/PF, normal human sera (NHS)] were normalized using the Box–Cox
transformation (Box and Cox, 1964). The transformed data were used to
compute the specificity of the ELISA. Significant differences between the
extinction data with BP sera and NHS in the ELISA were calculated with the
Wilcoxon test (SAS system).
RESULTS
BPAG2-specific autoantibodies are detected in the sera of BP
and PG patients by ELISA Sera from patients with BP (n 5 39),
PG (n 5 10), PV/PF (n 5 15), and NHS (n 5 18) were incubated
(at a dilution of 1:20) with BV13 protein (ECD of BPAG2) immobilized
onto ELISA plates. Binding of BPAG2-specific antibodies was visualized
by the formation of a yellow dye catalyzed by a second, AP-labeled
goat anti-human antibody. Proteins from WT baculovirus-infected
insect cells that were also purified over nickel agarose served as a
control. The BPAG2-specific serum reactivity of each sample was
determined by subtracting the reactivity against the WT baculovirus
from its reactivity versus BV13. The results of these analyses are shown
in Fig 1. By the Wilcoxon test, differences in the BPAG2 reactivities
were highly significant (p , 0.0001) between sera from BP/PG patients
and control sera (including all of the NHS and PV/PF sera). The cut-
off value of the ELISA was set at an ODBV13-WT value of 0.11 that
was equal to the mean value of the negative control sera 1 1 SD.
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Figure 1. Scatter blot of reactivities of sera from patients with BP, PG,
PV/PF, and NHS in the ELISA with BV13 protein (BPAG2). Immobilized
BV13 protein (ECD of BPAG2) was incubated with sera (diluted at 1:20) from
adult patients with BP, PG, PV/PF, and NHS. Binding of serum antibodies to
immobilized BV13 was visualized by incubation with nitroblue tetrazolium and
5-bromo-4-chloro-3-indolyl-phosphate after incubation with a second, AP-
conjugated goat anti-human IgG (1:5000) and was expressed as OD at 405 nm.
By the Wilcoxon test, differences in the BPAG2 reactivities were highly
significant (p , 0.0001) between sera from BP/PG patients and control sera
(NHS and PV/PF sera). The cut-off of the ELISA was set at an ODBV13–WT
value of 0.11 that was equal to the mean value of the negative control sera 1
1 SD. This cut-off is indicated by the spaced line.
Table I. Sensitivities of ELISA and the western blot of BV13
(BPAG2) protein and immunoprecipitation with epidermal
keratinocyte extracts in the detection of BPAG2-specific
autoantibodies in sera of patients with BPa
Patient ELISA (BV13) Western blot (BV13) IP (BPAG2)
BP2 1:400* pos. BPAG2
BP3 1:400 pos. BPAG1, BPAG2
BP8 1:400 pos. BPAG1, BPAG2
BP10 1:200 neg. BPAG2
BP11 1:200 pos. BPAG2
BP18 1:50 pos. BPAG1, BPAG2
BP20 1:20 neg. BPAG2
BP21 1:20 neg. BPAG2
BP22 1:20 neg. BPAG1, BPAG2
BP23 1:20 neg. BPAG1, BPAG2
BP25 1:20 neg. BPAG2
BP26 1:20 neg. BPAG1, BPAG2
BP27 1:100 neg. BPAG2
BP28 1:200 pos. BPAG2
BP29 1:200 neg. BPAG1
BP30 1:200 neg. BPAG1
aBV13, extracellular portion of BPAG2; IP, immunoprecipitation with biosynthetically
radiolabeled BPAG1/BPAG2 antigen from epidermal keratinocyte extracts; *, antibody
titers.
Using this cut-off value, 35 of 39 BP sera (89.7%) and 10 of 10 PG
sera (100%) reacted specifically with BV13 protein (BPAG2) and only
one of 18 NHS and none of 15 PV/PF sera reacted in the ELISA. A
higher cut-off value (i.e., mean of negative sera 1 2 SD) led to false
negative results (i.e., exclusion of three BP and one PG sera, which
definitively contained BPAG2-specific autoantibodies, as determined
by IP with epidermal extracts) without much improvement of the
specificity, and was therefore not applied.
Differential sensitivities of BV13-ELISA, western blot of BV13
protein, and IP with extracts from epidermal keratinocytes in
the detection of BPAG2-specific antibodies Sera of 16 adult
patients with BP that were reactive in the ELISA with BV13 (BPAG2)
were also tested in the western blot of BV13 protein and the IP with
biosynthetically radiolabeled epidermal keratinocyte extracts to compare
the sensitivities of these in vitro tests (Table I). Fourteen of 16 (87.5%)
Table II. Comparison of BPAG2-specific serum reactivities
(ELISA) and severity of skin disease in patients with BP
Patient Disease activitya BPAG2-antibody titer
BP1 1 1 1 (trunk) .1:400
BP2 1 1 1 (trunk, arms) 1:400
BP3 1 1 1 (abdomen, arms) .1:400
BP4 1 1 1 (trunk) 1:400
BP5 1 1 1 (trunk, extremities) .1:400
BP6 1 1 1 (abdomen, arms) 1:400
BP7 1 1 1 (trunk, extremities) 1:400
BP8 1 1 1 (trunk) 1:400
BP9 1 1 1 (trunk, extemities) 1:200
BP10 – 1:200
BP11 1 1 (upper trunk) 1:200
BP12 – 1:200
BP13 1 1 1 (trunk, extremities) 1:200
BP14 – 1:100
BP15 1 (arms) 1:50
BP16 1 (trunk) 1:50
BP17 1 1 1 (trunk) 1:50
BP18 1 1 (trunk) 1:50
BP19 1 (trunk) 1:50
BP20 1 1 1 (trunk) 1:20
BP21 1 (oral erosions, neck) 1:20
BP22 1 (arms) 1:20
BP23 1 1 1 (trunk, legs) 1:20
BP24 1 1 1 (trunk) 1:20
BP25 – 1:20
BP26 1 1 (trunk, legs) 1:20
BP27 1 1 1 (trunk, extremities) 1:100
BP28 1 1 (trunk, extremities) 1:200
a1 1 1, disseminated bullae; 1 1, bullae at limited areas; 1, few bullae or erosions;
–, no skin lesions.
BP sera reactive in the ELISA of BV13 (BPAG2) also showed reactivity
for BPAG2 in the IP. In contrast, only six of these 16 (37.5%) BP sera
reacted in the western blot of BV13. To investigate whether the lower
sensitivity of the western blot was caused by further denaturation (upon
boiling) of the recombinant protein, nine BPAG2-reactive BP sera
were analyzed in the ELISA with nonboiled versus boiled immobilized
BV13 protein (2 µg per well). In the ELISA with boiled BV13 protein,
reactivities of five BP sera with BPAG2-specific antibody titers of
1:400 (as determined in the ELISA with nonboiled BV13) were
uniformly reduced to titers of ,1:100, whereas BPAG2-specific
reactivities of four additional BP sera (antibody titers of 1:100 in the
ELISA with nonboiled BV13) could not be detected at a dilution of
1:20. Together, these results suggest a correlation between the results
of ELISA and IP, and indicate that the western blot of BV13 is less
sensitive than the ELISA in detecting BPAG2-specific autoantibodies.
Titration of BPAG2-specific antibodies in the sera of BP and
PG patients The ELISA with BV13 protein was also performed
with serial dilutions (1:20–1:400) of BP sera to quantitatively determine
serum reactivity to BPAG2. Titers of BPAG2-specific antibodies were
compared with the extent of skin disease in 28 adult BP patients whose
clinical course of disease was well characterized (Table II). Twelve of
19 BP patients with extensive skin disease had high titers of antibodies
against BPAG2 (1:200–ù1:400). In contrast, six of 19 BP patients with
extensive skin disease had low BPAG2-specific antibody titers (1:20–
1:50); one severely affected BP patient had BPAG2-specific antibody
titers of 1:100. Six of nine sera from BP patients with few or no skin
symptoms had low titers (1:20–1:50) of BPAG2-specific antibodies
whereas three BP patients with no skin symptoms had BPAG2-specific
antibody titers of 1:100–1:200.
DISCUSSION
In this study, we have developed an ELISA utilizing a baculovirus-
encoded recombinant protein consisting of the ECD of human BPAG2
to detect autoantibodies against BPAG2, one of the two major
autoantigens of BP. The eukaryotic baculovirus expression system was
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chosen because it generates recombinant proteins that frequently exhibit
post-translational modifications and conformation similar to those of
the authentic protein (Kidd and Emery, 1993). Using this ELISA,
antibody reactivity to BPAG2 was detected in the majority (89.7%) of
sera from adult patients with BP and in 100% of the sera from patients
with PG, a bullous autoimmune disease closely related to BP (Morrison
et al, 1988; Jenkins et al, 1995). In addition, our results indicate that
this ELISA is also highly specific in that only one of 33 negative
control sera (PV/PF sera; NHS) fell within the positive range in this test.
Previous studies using western blot of protein extracts from normal
human epidermis (Labib et al, 1986; Bernard et al, 1989; Robledo et al,
1990; Machado et al, 1992) showed that 35–50% of the sera from BP
patients contain autoantibodies against BPAG2. A recent large survey
study detected autoantibodies against BPAG2 in 129 of 263 (49%) of
BP sera by western blot using epidermal proteins (Ghohestani et al,
1996). The sensitivities of ELISA, western blot, and/or IP cannot be
directly compared mainly because the antigen and secondary antibodies
used for the detection of BPAG2-specific autoantibodies differed
between the tests. In this study, the ELISA was more sensitive than
the western blot of the identical BPAG2 recombinant in the detection
of autoantibodies specific for BPAG2 (Table I). Most likely, further
denaturation of the recombinant BPAG2 protein led to a loss of
epitopes recognized by BPAG2-reactive antibodies. This contention is
supported by the finding that the ELISA with boiled BV13 protein
was less sensitive than the ELISA with nonboiled BV13 protein in the
detection of BPAG2-specific autoantibodies. Consistent with our
findings with BP sera, a recent study detected autoantibodies against
type-VII collagen in sera of patients with epidermolysis bullosa acquisita
more readily by ELISA with a recombinant eukaryotic type-VII
collagen than by western blot of the identical recombinant protein
(Chen et al, 1997). The potential diagnostic value of the ELISA is
further supported by our IP studies using extracts of epidermal
keratinocytes (Table I). Our findings suggest that the ELISA has a
sensitivity comparable with the IP in which antigen-antibody reaction
occurs prior to denaturation by sodium dodecyl sulfate. For the clinical
routine, this ELISA with an eukaryotic protein containing the entire
ECD of BPAG2 may be very useful because: (i) it is easy to perform,
(ii) it is suitable for the rapid and simultaneous testing of many sera,
(iii) it allows for the quantitative analysis of BPAG2-specific antibody
titers, and (iv) it appears to be highly sensitive and specific.
Recently, Giudice et al established an ELISA for the detection of
BPAG2-specific antibodies using a prokaryotic (Escherichia coli-derived)
recombinant protein consisting of a noncollagenous 42 amino acid
long stretch of the ECD of BPAG2 (Giudice et al, 1994). Previous
studies indicated that this region adjacent to the membrane spanning
domain harbors the major immunodominant sites for BP sera (Giudice
et al, 1993). In their ELISA study, 53% of the BP sera and 71% of the
PG sera showed reactivity to BPAG2 (Giudice et al, 1994). This is in
contrast to a reactivity of 89.7% of BP sera and 100% of PG sera in
the ELISA of this study. Although one cannot directly compare these
two studies, it is likely that the ELISA of Giudice et al with a bacterial
recombinant protein may be less sensitive for the following reasons.
(i) In contrast to eukaryotic proteins, prokaryotic proteins frequently
lack post-translational modifications that may be critical for folding
and thus for conformation of the protein. We have no precise data on
the exact conformation of the recombinant BPAG2 protein (BV13)
used in this ELISA study. There are definitively imperfections in the
use of the baculovirus system with regard to the expression of
collagenous proteins (low prolyl hydoxylase activity). Currently, efforts
are being made to optimize the expression and assembly of recombinant
BPAG2 protein by coexpression of baculovirus-encoded prolyl
hydroxylase in the identical insect cell system. Because we did see
specific immunoreactivity of most BP and PG sera with BV13 protein,
the major B cell epitopes must be exposed on this recombinant. The
importance of conformational epitopes has been recently demonstrated
for the binding of pathogenic antibodies specific for desmoglein 3, the
autoantigen of PV (Amagai et al, 1994); in this study, a baculovirus-
derived desmoglein 3 protein, but not an E. coli-derived recombinant
protein, was able to remove all pathogenic autoantibodies from PV
sera. (ii) The MCW-1 region encompasses only a small portion of the
ECD of BPAG2 and may thus not contain all of the epitopes recognized
by BPAG2-specific circulating autoantibodies. This assumption is
supported by a recent study demonstrating that sera of patients with
cicatricial pemphigoid, a bullous autoimmune disease related to BP,
contain autoantibodies that react with at least two distinct regions
within the ECD of BPAG2 (Balding et al, 1996). An ELISA utilizing
the ECD of BPAG2 protein may thus allow for the detection of BPAG2-
reactive antibodies of heterogeneous specificity. The C terminus of
the ECD of BPAG2 (final 68 amino acids) that was not included in
the recombinant BV13 protein utilized in this study, does not harbor
major antibody epitopes of BPAG2 because (i) the majority of the
tested BP sera were reactive in the ELISA with BV13 and (ii) a recent
study by Zillikens et al demonstrated that the major antibody epitopes
of BPAG2 were clustered around the NC16 domain that is adjacent
to the membrane spanning region (Zillikens et al, 1997).
Recent observations suggested that the presence of BPAG2-specific
but not BPAG1-specific autoantibodies was a poor prognostic marker
in a cohort of 94 adult BP patients (Bernard et al, 1997). In addition,
the exclusive presence of BPAG2-specific autoantibodies in BP sera
appeared to be associated with an unusually long course of disease
(Venning et al, 1991). Together, these data suggest that quantitative
assessment of antibody reactivity to BPAG2 provides a prognostic
parameter of disease activity in BP. We thus compared the titers of
BPAG2-specific antibodies in the sera of BP patients with the extent
of their skin involvement (Table II). Our results demonstrate that sera
of 64% of the BP patients with extensive skin disease had high titers
of anti-BPAG2 antibodies, whereas 67% of the sera from BP patients
with few or no skin symptoms had low titers of BPAG2-specific
antibodies. Even though end point titration of BP and PG sera provides
only a semiquantitative analysis of BPAG2-specific autoantibodies,
these preliminary observations suggest that the concentration of anti-
BPAG2 IgG was not always related to the extent of skin disease in
BP patients.
The novel ELISA described here that utilizes an eukaryotic form of
the ECD of BPAG2 is thus a sensitive and specific technique for the
detection of BPAG2-reactive antibodies in the sera of patients with
BP and PG. The detection of BPAG2-specific autoantibodies in the
majority of BP and PG sera lends additional support to the assumption
that BPAG2 is a primary target molecule in the pathogenesis of BP
and PG.
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